Journals / Turkish Neurosurgery / 2017 / Cilt: 27 - Sayı: 1

Is Positive Staining of Non-Functioning Pituitary Adenomas for Luteinizing Hormone Associated with a Poor Prognosis?

Pages
8–13
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Thus, additional studies are required to assess the relationship between LH positivity and poor prognosis in patients with NFPAs.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIm: The aim of this study was to assess the relationships among immunohistochemical staining patterns and prognostic factors in patients with non-functioning pituitary adenoma (NFPA). mATERIAl and mEThODS: The study included 103 patients who had undergone pituitary surgery for NFPAs.
📊
Key Findings & Data:RESUlTS: Recurrence rates were higher for NFPAs with large initial tumor volume and preoperative cavernous sinus invasion.
💡
Conclusion & Impact:Thus, additional studies are required to assess the relationship between LH positivity and poor prognosis in patients with NFPAs.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

AIm: The aim of this study was to assess the relationships among immunohistochemical staining patterns and prognostic factors in patients with non-functioning pituitary adenoma (NFPA). mATERIAl and mEThODS: The study included 103 patients who had undergone pituitary surgery for NFPAs. The prognostic factors evaluated were initial tumor size, cavernous sinus invasion, compression of the optic chiasm, recurrence, residual tissue, reoperation, and hypopituitarism. RESUlTS: Recurrence rates were higher for NFPAs with large initial tumor volume and preoperative cavernous sinus invasion. Tumor recurrence rates were higher for NPFAs positive (55.6%) than negative (10.3%) for luteinizing hormone (LH). Reoperation rate, but not recurrence rate, was higher in patients with tumors positive than negative for follicle-stimulating hormone (FSH) group. Recurrence and reoperation rates were lowest in patients with null-cell adenomas. CONClUSION: In contrast to previous studies, we observed a higher recurrence rate in LH-positive than in LH-negative adenomas. To our knowledge, this is the first study showing an association between LH positivity and poorer prognosis; and in addition, optimal outcomes in patients with null-cell adenomas. Thus, additional studies are required to assess the relationship between LH positivity and poor prognosis in patients with NFPAs.

🔖

Cite This Article

KURTSOY, A., TUCER, B., DURAK, A. C., OZASLAN, E., OZTURK, F., ERTEN, S., DIRI, H., SIMSEK, Y., BAYRAM, F. (2022). Is Positive Staining of Non-Functioning Pituitary Adenomas for Luteinizing Hormone Associated with a Poor Prognosis?. Turkish Neurosurgery, Cilt: 27 - Sayı: 1, 8–13. https://ajindex.com/articles/616937

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Asa SL, Ezzat S: The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev 19(6):798-827, 1998 2. Asa SL, Kovacs K: Clinically non-functioning human pituitary adenomas. Can J Neurol Sci 19(2):228-235, 1992 3. Bradley KJ, Wass JA, Turner HE: Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently. Clin Endocrinol (Oxf) 58(1):59- 64, 2003 4. Brochier S, Galland F, Kujas M, Parker F, Gaillard S, Raftopoulos C, Young J, Alexopoulou O, Maiter D, Chanson P: Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: A study of 142 patients. Eur J Endocrinol 163(2):193-200, 2010 5. Colao A, Grasso LF, Pivonello R, Lombardi G: Therapy of aggressive pituitary tumors. Expert Opin Pharmacother 12(10):1561-1570, 2011 6. Cooper O, Ben-Shlomo A, Bonert V, Bannykh S, Mirocha J, Melmed S: Silent corticogonadotroph adenomas: Clinical and cellular characteristics and long-term outcomes. Horm Cancer 1(2):80-92, 2010 7. Cooper O, Melmed S: Subclinical hyperfunctioning pituitary adenomas: The silent tumors. Best Pract Res Clin Endocrinol Metab 26(4):447-460, 2012 8. Ferrante E, Ferraroni M, Castrignano T, Menicatti L, Anagni M, Reimondo G, Del Monte P, Bernasconi D, Loli P, FaustiniFustini M, Borretta G, Terzolo M, Losa M, Morabito A, Spada A, Beck-Peccoz P, Lania AG: Non-functioning pituitary adenoma database: A useful resource to improve the clinical management of pituitary tumors. Eur J Endocrinol 155(6):823- 829, 2006 9. Greenman Y, Ouaknine G, Veshchev I, Reider-Groswasser II, Segev Y, Stern N: Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: Markers of tumour quiescence and regrowth. Clin Endocrinol (Oxf) 58(6):763- 769, 2003 10. Greenman Y, Stern N: Non-functioning pituitary adenomas. Best Pract Res Clin Endocrinol Metab 23(5):625-638, 2009 11. Ioachimescu AG, Eiland L, Chhabra VS, Mastrogianakis GM, Schniederjan MJ, Brat D, Pileggi AV, Oyesiku NM: Silent corticotroph adenomas: Emory University cohort and comparison with ACTH-negative nonfunctioning pituitary adenomas. Neurosurgery 71(2):296-304, 2012 12. Klibanski A: Nonsecreting pituitary tumors. Endocrinol Metab Clin North Am 16(3):793-804, 1987 13. Losa M, Donofrio CA, Barzaghi R, Mortini P: Presentation and surgical results of incidentally discovered nonfunctioning pituitary adenomas: Evidence for a better outcome independently of othe